Small molecule · developed by Praxis Precision Medicines
Relutrigine (PRAX-562) is an oral drug studied in developmental and epileptic encephalopathy 1.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07010471 | Phase 3 | Developmental and Epileptic Encephalopathy 1 | Active not recruiting | PRAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Developmental and Epileptic Encephalopathy 1
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRAX page.
See PRAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRAX catalysts and pipeline →